This database contains 102 studies, archived under the term: "alzheimer’s disease"
Click here to filter this large number of results.
A chronic grief intervention for dementia family caregivers in long-term care
Paun, O.,
Farran, C. J.,
Fogg, L.,
Loukissa, D.,
Thomas, P. E.,
Hoyem, R.
Dementia caregivers do not relinquish their role after placing family members in long-term care and they experience increased chronic grief. The Chronic Grief Management Intervention (CGMI) is a12-week group-based program that uses guided discussion to deliver knowledge of Alzheimer’s or a related dementia and teach skills in communication, conflict resolution, and chronic grief management in […]
Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: A case report and literature review of the evidence for use of these Kampo herbal formulae
Okamoto, Hideki,
Chino, Atsushi,
Hirasaki, Yoshiro,
Ueda, Keigo,
Iyo, Masaomi,
Namiki, Takao
Background: Yokukan-san, a Japanese traditional herbal (Kampo) prescription, has recently gathered increasing attention due to accumulating reports showing its remarkable efficacy in treating a wide variety of diseases refractory to conventional medicine as well as the behavioral and psychological symptoms of dementia. As yokukan-san has become broadly integrated with conventional medicine, augmentation therapy with other […]
Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer’s disease
O'Caoimh, Rónán,
Healy, Liam,
Gao, Yang,
Svendrovski, Anton,
Kerins, David M.,
Eustace, Joseph,
Kehoe, Patrick Gavin,
Guyatt, Gordon,
Molloy, D. William
Background: Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may also improve exercise tolerance in functionally impaired older adults with normal cognition, suggesting that CACE-Is may positively influence activities of daily living (ADL) in dementia.; Objective: To compare rates of decline in patients […]
18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias
O'Brien, J. T.,
Firbank, M. J.,
Davison, C.,
Barnett, N.,
Bamford, C.,
Donaldson, C.,
Olsen, K.,
Herholz, K.,
Williams, D.,
Lloyd, J.
Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and […]
The impact of supplemental macular carotenoids in Alzheimer’s disease: A randomized clinical trial
Nolan, John M.,
Loskutova, Ekaterina,
Howard, Alan,
Mulcahy, Riona,
Moran, Rachel,
Stack, Jim,
Bolger, Maggie,
Coen, Robert F.,
Dennison, Jessica,
Akuffo, Kwadwo Owusu,
Owens, Niamh,
Power, Rebecca,
Thurnham, David,
Beatty, Stephen
Background: Patients with Alzheimer’s disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when compared to control subjects. Objective: To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with AD versus controls. Methods: A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and […]
Cognitive-motor intervention in Alzheimer’s disease: Long-term results from the Maria Wolff trial
Mũniza, Ruben,
Serraa, Cristina Massegú,
Reisberga, Barry,
Rojo, José Manuel,
del Ser, Teodoro,
Casanova, Jordi Pẽna,
Olazarán, Javier
Background: Little is known about the long-term acceptance and effects of cognitive and motor stimulation interventions (CMSI) in Alzheimer’s disease (AD). Objective: To evaluate a replicable CMSI program for mild cognitive impairment (MCI) and mild-to-moderate AD persons. Methods: Eighty-four non-institutionalized subjects with AD were randomized to receive either CMSI, administered by a single care provider, […]
A randomized clinical trial of Behavioral Activation (BA) therapy for improving psychological and physical health in dementia caregivers: results of the Pleasant Events Program (PEP)
Moore, Raeanne C.,
Chattillion, Elizabeth A.,
Ceglowski, Jennifer,
Ho, Jennifer,
von Känel, Roland,
Mills, Paul J.,
Ziegler, Michael G.,
Patterson, Thomas L.,
Grant, Igor,
Mausbach, Brent T.
Dementia caregiving is associated with elevations in depressive symptoms and increased risk for cardiovascular diseases (CVD). This study evaluated the efficacy of the Pleasant Events Program (PEP), a 6-week Behavioral Activation intervention designed to reduce CVD risk and depressive symptoms in caregivers. One hundred dementia family caregivers were randomized to either the 6-week PEP intervention […]
Donepezil improves gait performance in older adults with mild Alzheimer’s disease: A phase II clinical trial
Montero-Odasso, Manuel,
Muir-Hunter, Susan W.,
Oteng-Amoako, Afua,
Gopaul, Karen,
Islam, Anam,
Borrie, Michael,
Wells, Jennie,
Speechley, Mark
Background: Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer’s disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. Objective: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, […]
Visuospatial memory and neuroimaging correlates in mild cognitive impairment
Mitolo, Micaela,
Gardini, Simona,
Fasano, Fabrizio,
Crisi, Girolamo,
Pelosi, Annalisa,
Pazzaglia, Francesca,
Caffarra, Paolo
Spatial abilities decline in normal aging and decrease faster and earlier in Alzheimer’s disease (AD), but these deficits are under investigated. The main goals of this study were to assess visuospatial memory abilities in mild cognitive impairment (MCI), in order to verify whether these tasks might be valid as the standard cognitive test to differentiate […]